Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 12/20 | 0.62 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.61 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.61 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.61 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23050281 | 0.89 | MAPK1 (0.62) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL9959335 | 0.88 | MAPK1 (0.62) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL14872686 | 0.81 | MAPK1 (0.65) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL2866791 | 0.80 | MAP2K4 (0.69) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL1145076 | 0.79 | MAP2K4 (0.57) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL31504557 | 0.79 | MAP2K4 (0.57) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL22166082 | 0.79 | MAPK1 (0.64) | MAPK1 | |
| SCHEMBL16619923 | 0.78 | MAPK1 (0.57) | MAPK1 | |
| SCHEMBL21338430 | 0.78 | MAPK1 (0.53) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL2868589 | 0.77 | MAP2K4 (0.69) | MAPK1MAP2K4MAPKAPK3MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2584903-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2584903-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MAPK1, MAPK6, MAPK3 | MAPK1 1/4885MAP2K4 92/4885MAPKAPK3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.